Literature DB >> 16219533

Proteomic signature of myeloproliferation and neutrophilia: analysis of serum and plasma from healthy subjects given granulocyte colony-stimulating factor.

David Stroncek1, Stefanie Slezak, Hanh Khuu, Christopher Basil, John Tisdale, Susan F Leitman, Francesco M Marincola, Monica C Panelli.   

Abstract

OBJECTIVE: Proteomic analysis could improve our understanding of the mechanisms and consequences of myeloproliferation. Healthy subjects treated with granulocyte colony-stimulating factor (G-CSF) were used as a model of myeloproliferation.
METHODS: Levels of 80 soluble factors were measured by enzyme-linked immunosorbent assay before and after 5 days of G-CSF. Both serum and plasma levels were measured to generate a comprehensive profile and determine whether serum or plasma best portrays biological and physiological changes.
RESULTS: Comparison of samples collected prior to G-CSF demonstrated that 44 factors differed between serum and plasma. Concentrations of several growth factors and chemokines were greater in serum than in plasma, while the opposite was true for several interleukins. Following G-CSF serum levels of 14 factors and plasma levels of 15 factors changed. Eleven increased in both serum and plasma, including cell adhesion molecules (vascular cell adhesion molecule-1, E-selectin, and L-selectin), matrix metalloproteases (MMP-1, -8, and -13), cytokine receptors (tumor necrosis factor receptor 1 and 2, and interleukin-2 receptor), the acute phase reactant, serum amyloid A, and a growth factor, hepatocyte growth factor.
CONCLUSION: Some protein levels differ markedly in serum and plasma. Myeloproliferation is associated with changes in the levels of several proteases, adhesion molecules, and cytokines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16219533     DOI: 10.1016/j.exphem.2005.06.029

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  7 in total

1.  Are serum cytokines sensitive and specific enough to prognosticate in aspergillosis?

Authors:  Dimitrios P Kontoyiannis
Journal:  J Infect Dis       Date:  2011-05-15       Impact factor: 5.226

2.  Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia.

Authors:  Steven M Kornblau; David McCue; Neera Singh; Wenjing Chen; Zeev Estrov; Kevin R Coombes
Journal:  Blood       Date:  2010-08-02       Impact factor: 22.113

3.  Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a.

Authors:  Stefanie Slezak; Ping Jin; Lorraine Caruccio; Jiaqiang Ren; Michael Bennett; Nausheen Zia; Sharon Adams; Ena Wang; Joao Ascensao; Geraldine Schechter; David Stroncek
Journal:  J Transl Med       Date:  2009-06-04       Impact factor: 5.531

4.  Targeted antagonism of CXCR4 mobilizes progenitor cells under investigation for cardiovascular disease.

Authors:  Arnon Blum; Richard W Childs; Aleah Smith; Sushmitha Patibandla; Gloria Zalos; Leigh Samsel; J Philip McCoy; Gary Calandra; Gyorgy Csako; Richard O Cannon
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

5.  Comparison of proteomic profiles of serum, plasma, and modified media supplements used for cell culture and expansion.

Authors:  Saleh Ayache; Monica C Panelli; Karen M Byrne; Stefanie Slezak; Susan F Leitman; Francesco M Marincola; David F Stroncek
Journal:  J Transl Med       Date:  2006-10-04       Impact factor: 5.531

6.  Circulating cytokines and small molecules follow distinct expression patterns in acute myeloid leukaemia.

Authors:  Mirazul Islam; Elsa Haniffah Mohamed; Ezalia Esa; Nor Rizan Kamaluddin; Shamsul Mohd Zain; Yuslina Mat Yusoff; Yassen Assenov; Zahurin Mohamed; Zubaidah Zakaria
Journal:  Br J Cancer       Date:  2017-09-12       Impact factor: 7.640

7.  Granulocyte colony-stimulating factor (G-CSF) increases histone-complexed DNA plasma levels in healthy volunteers.

Authors:  Christian Schoergenhofer; Michael Schwameis; Philipp Wohlfarth; Christine Brostjan; Simon T Abrams; Cheng-Hock Toh; Bernd Jilma
Journal:  Clin Exp Med       Date:  2016-03-22       Impact factor: 3.984

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.